Risperdal Consta for Bipolar Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2008

Study Completion Date

December 31, 2009

Conditions
Bipolar I Disorder
Interventions
DRUG

Injectable Risperidone (Consta) or oral antipsychotic

"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"

Trial Locations (4)

15132

Mon-Yough Community Services, Inc., McKeesport

15801

Dubois Regional Medical Center, DuBois

15017-1599

Mayview State Hospital, Bridgeville

15213-2593

Western Psychiatric Institute and Clinic, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00177164 - Risperdal Consta for Bipolar Disorder | Biotech Hunter | Biotech Hunter